

# Resource Summary Report

Generated by [nidm-terms](#) on Aug 9, 2026

## HOMA2 calculator

RRID:SCR\_023419

Type: Tool

### Proper Citation

HOMA2 calculator (RRID:SCR\_023419)

### Resource Information

**URL:** <https://www.dtu.ox.ac.uk/homacalculator/>

**Proper Citation:** HOMA2 calculator (RRID:SCR\_023419)

**Description:** Software tool used to calculate Homeostasis Model Assessment which takes account of variations in hepatic and peripheral glucose resistance, increases in insulin secretion curve for plasma glucose concentrations and contribution of circulating proinsulin. Provides access to HOMA2 model for researchers who wish to use model derived estimates of %B and %S, rather than linear approximations.

**Synonyms:** HOMA Calculator

**Resource Type:** software resource, software application

**Keywords:** calculate Homeostasis Model Assessment, Homeostasis Model Assessment, HOMA calculator

**Availability:** Free, Available for download, Freely available

**Resource Name:** HOMA2 calculator

**Resource ID:** SCR\_023419

**Record Creation Time:** 20230328T050203+0000

**Record Last Update:** 20260808T190534+0000

### Ratings and Alerts

No rating or validation information has been found for HOMA2 calculator.

No alerts have been found for HOMA2 calculator.

### Data and Source Information

## Usage and Citation Metrics

We found 81 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

Paudel P, et al. (2026) Reference intervals for fasting insulin and insulin-related indices in healthy adults: a cross-sectional study in Gandaki Province, Nepal. *BMJ open*, 16(3), e109523.

Yang Y, et al. (2026) Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria and diabetic kidney disease in adult type 2 diabetes: a cross-sectional study. *BMC endocrine disorders*, 26(1).

Yang Y, et al. (2026) Continuous glucose monitoring-derived glycemic variability and low skeletal muscle mass in middle-aged and older adults with type 2 diabetes mellitus: an analysis using AWGS 2025 criteria. *Diabetology & metabolic syndrome*, 18(1).

Li C, et al. (2026) Serum 25-hydroxyvitamin D levels and their association with ketosis in patients with newly diagnosed type 2 diabetes. *Medicine*, 105(17), e48304.

Bhaganagarapu LS, et al. (2026) Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure - A Randomized Controlled Trial. *Endocrine, metabolic & immune disorders drug targets*, 26.

Mellergaard M, et al. (2026) Circulating Liver-Derived and CD36+ Extracellular Vesicles Correlate With Ectopic Liver Fat and Markers of Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease and Decrease During Weight Loss Intervention. *Journal of extracellular vesicles*, 15(3), e70257.

Chen C, et al. (2026) Clustering-based subgroups of type 2 diabetes mellitus and their associations with diabetes remission after bariatric surgery. *Chinese medical journal*, 139(1), 145.

Zheng H, et al. (2026) Insights on accelerometer-measured 24-hour movement behaviour across type 2 diabetes sub-phenotypes in the Asian population. *Diabetes & vascular disease research*, 23(2), 14791641261431769.

Li Z, et al. (2026) Hybrid PET/fMRI reveals interactive effects of T2DM and MCI on cerebral glucose metabolism and ALFF. *Frontiers in endocrinology*, 17, 1778600.

Decarnoncle M, et al. (2026) Effects of NAD<sup>+</sup> repletion with Nicotinamide riboside on obesity-induced chronic kidney disease and renal cell lipotoxicity. *Scientific reports*, 16(1).

Boige V, et al. (2026) Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(10), 2088.

Roca Suarez AA, et al. (2025) Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease. *eGastroenterology*, 3(1), e100159.

Almotairi R, et al. (2025) Evaluating the Impact of rs4025935, rs71748309, rs699947, and rs4646994 Genetic Determinants on Polycystic Ovary Syndrome Predisposition-A Case-Control Study. *Life (Basel, Switzerland)*, 15(4).

Aliyu U, et al. (2025) Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes. *Diabetes, obesity & metabolism*, 27(8), 4469.

Galderisi A, et al. (2025) Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of  $\beta$  Cell Function. *The Journal of clinical endocrinology and metabolism*, 110(11), 3168.

Tas E, et al. (2025) The association between hepatic steatosis, vitamin D status, and insulin resistance in adolescents with obesity. *Obesity pillars*, 14, 100173.

Jagannathan R, et al. (2025) Subtypes of Type 2 Diabetes and Prediabetes: Mortality and Excess Life Lost in South Asians. *Research square*.

Shen X, et al. (2025) Cerebral Small Vessel Disease Outperforms Brain Atrophy as an Imaging Biomarker in Diabetic Retinopathy. *Journal of diabetes*, 17(2), e70058.

Liweleya S, et al. (2025) Metabolic and inflammatory axes of insulin resistance in normoglycemic adults with high HIV burden. *PLOS global public health*, 6(1), e0005589.

Askeland A, et al. (2025) Non-invasive liver fibrosis markers are increased in obese individuals with non-alcoholic fatty liver disease and the metabolic syndrome. *Scientific reports*, 15(1), 10652.